17 July 2007
| In EUR millions |
|
At current USD rates |
At constant USD rates |
| |
2006 |
2007 |
Change |
2007 |
Change |
| First quarter |
18.3 |
21.2 |
+15.6% |
22.5 |
+22.9% |
| Second quarter |
16.4 |
20.6 |
+26.1% |
21.6 |
+32.3% |
| First half |
34.7 |
41.8 |
+20.5% |
44.1 |
+27.3% |
| Average USD exchange rate |
1.2198 |
1.3312 |
|
1.2198 |
|
Naturex had an excellent second quarter with revenues up 32.3% at constant USD rates (up 26.1% at current USD rates) which confirms the solid performance posted in the first quarter.
Revenues for the first half of the year totaled EUR 41.8 million, up 27.3% at constant USD rates (up 20.5% at current USD rates).
This rapid development is due to both the broadening of Naturex’s scope, with the acquisitions of Hammer Pharma in January and HP Botanicals in April, and sustained organic growth (+13.2% at constant USD rates for the Group’s former scope).
Acquisitions
In line with its strategy, Naturex is continuing its policies of sustained organic growth and acquisitions alongside each other and has set a revenue target of EUR 100 million in 2008.
Due diligence is currently underway for the planned acquisition of a US business generating approximately USD 10 million in revenues.
Moreover, new projects are being studied both in Europe and North America.